文献速递产科母胎医学

法国III级产科队列中新生儿先天性巨细胞病毒感染普遍筛查的可行性与相关性

Universal newborn screening for congenital cytomegalovirus infection: feasibility and relevance in a French type-III maternity cohort.
PubMed 文献 · BJOG · 2021-11-23

在法国Clamart的III级产科2016-2020年连续纳入15341例新生儿,出生时唾液CMV PCR筛查阳性者用尿CMV PCR确认。先天性巨细胞病毒感染(cCMVI)出生患病率0.4%(95%CI 0.3-0.5),62%的病例无产前或新生儿征象及母亲孕期感染史。唾液PCR预测cCMVI的最佳阈值为356(2.55 log)拷贝/ml,ROC曲线下面积0.97。超过90%的72名受访员工认为筛查简便快速,无家长拒绝。

要点

  • 15341例新生儿中63例确诊cCMVI,出生患病率0.4%(95%CI 0.3-0.5)。
  • 62%(39/63)的cCMVI病例无产前或新生儿征象及母亲孕期感染史,仅普遍筛查可发现。
  • 唾液CMV PCR预测cCMVI的最佳阈值为356(2.55 log)拷贝/ml,ROC曲线下面积0.97。

核心结论

  • 用唾液样本CMV PCR进行cCMVI普遍筛查可行,且为家长和医护人员高度接受。
  • 超过半数(62%)的病例无产前或新生儿cCMVI征象或母亲孕期CMV感染史,若无普遍筛查很可能不会被诊断。

研究设计与样本

  • 回顾性、基于人群的队列研究,2016-2020年在法国Clamart的III级产科进行。
  • 所有连续出生的新生儿在出生时接受唾液CMV PCR,阳性者用尿CMV PCR确认或排除cCMVI。
  • 对母亲感染进行前瞻性和回顾性特征描述,用ROC曲线分析评估唾液PCR性能,并通过问卷调查评估员工对筛查的接受度。

主要发现

  • 15341例受检新生儿中63例患cCMVI,出生患病率为0.4%(95%CI 0.3-0.5)。
  • 50%的病例母亲感染为孕期非原发感染(NPI)。
  • cCMVI为预期或疑似(母亲原发感染[PI]、产前或新生儿征象)者24/63例(38%),意外发现者39/63例(62%)。
  • 预测cCMVI的最佳唾液CMV阈值为356(2.55 log)拷贝/ml(95%CI 2.52 log-3.18 log),ROC曲线下面积为0.97。
  • 72名受访员工中超过90%报告筛查简便快速,无家长拒绝筛查。

关键数值与推荐

  • 唾液CMV PCR预测cCMVI的最佳阈值为356(2.55 log)拷贝/ml(95%CI 2.52 log-3.18 log)。
  • 唾液CMV PCR的ROC曲线下面积为0.97。
  • cCMVI出生患病率为0.4%(95%CI 0.3-0.5)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Evaluation of relevance and feasibility of universal newborn congenital cytomegalovirus infection (cCMVI) screening in saliva. DESIGN: Retrospective, population-based cohort study. SETTING: Clamart, France, 2016-2020. POPULATION: All neonates born consecutively in our level III maternity unit. METHODS: CMV PCR in saliva for all neonates at birth, and, if positive, CMV PCR in urine to confirm or exclude cCMVI. Prospective and retrospective characterisation of maternal infections. ROC curve analysis to assess saliva PCR performances. Acceptability of screening among staff members evaluated by a survey. MAIN OUTCOME MEASURES: Number of cCMVI neonates; number of expected and unexpected cCMVI. RESULTS: Among 15 341 tested neonates, 63 had cCMVI (birth prevalence of 0.4%, 95% CI 0.3-0.5). In 50% of cases, maternal infection was a non-primary infection (NPI) during pregnancy. cCMVI was expected or suspected (maternal primary infection [PI], antenatal or neonatal signs) in 24/63 neonates (38%), and unexpected in 39/63 neonates (62%). The best CMV saliva threshold to predict cCMVI was 356 (2.55 log) copies/ml [95% CI 2.52 log-3.18 log], with an area under the ROC curve of 0.97. Over 90% of the 72 surveyed staff members reported that the screening was easy and quick. No parent refused the screening. CONCLUSIONS: Universal screening for cCMVI with CMV PCR on saliva samples is feasible and highly acceptable to parents and healthcare providers. Over half (62%) of the cases had no prenatal/neonatal signs of cCMVI or a maternal history of CMV infection during pregnancy and would probably not have been diagnosed without universal screening. TWEETABLE ABSTRACT: In 62% of congenital cytomegalovirus infection cases, only universal neonatal screening in saliva can detect infection.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Letamendia-Richard E, Périllaud-Dubois C, de La Guillonnière L, et al. Universal newborn screening for congenital cytomegalovirus infection: feasibility and relevance in a French type-III maternity cohort. BJOG. 2021. PMID: 34726316. doi:10.1111/1471-0528.16992

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。